The determination of the prevalence of polycystic ovary syndrome amongst women previously diagnosed with type II diabetes mellitus. PCOS is an extremely commom disorder effecting 6% of women of reproductive age in the United States. Women with PCOS are at 2.75 times increased risk for development of type II diabetes mellitus and impaired glucose intollerance than weight matched controls with a disease of prevalence of 30-35% for impaired glucose intolerance and 7-10% for type II diabetes mellitus at ages less than 45. There is presently no literature concerning the prevalence of polycystic ovary syndrome in women previously diagnosed with type II diabetes mellitus. These women are at increased risk of development of cardiovascular disease, dyslipidemia (fat metabolism problems), high blood pressure, and endometrial, breast, and ovarian cancer. The need to diagnose the possibly highly prevalent, chronic, anovulator state and its treatment are self-evident.
The aim of this protocol is to determine the frequency of PCOS in women who visit the diabetes specialty clinic with type II diabetes mellitus. Some will have already been diagnosed with PCOS. Women between the ages of 18 and 45 who have presented to the diabetes clinic at least once over the past 5 years with diagnosis or treatment of type II diabetes will be contacted by phone to determine a brief menstral history including the number of menstrual periods per year, the number of pregnancies and live births, previous birth control and fertility techniques. Women who give a history of less than nine periods per year will be invited to participate in the study at the GCRC where a questionnaire will be completed and a physical exam will be given. The presence and degree of abnormal hair growth will be determined. Serum samples will be drawn for lab tests.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000065-38
Application #
6419314
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
1977-12-01
Project End
2002-11-30
Budget Start
Budget End
Support Year
38
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Type
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298
Holkova, Beata; Yazbeck, Victor; Kmieciak, Maciej et al. (2017) A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. Leuk Lymphoma 58:1349-1357
Corey, Kathleen E; Vuppalanchi, Raj; Vos, Miriam et al. (2015) Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 60:360-7
Eaton, J E; Juran, B D; Atkinson, E J et al. (2015) A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease. Aliment Pharmacol Ther 41:980-90
Worthington Jr, Everett L; Berry, Jack W; Hook, Joshua N et al. (2015) Forgiveness-reconciliation and communication-conflict-resolution interventions versus retested controls in early married couples. J Couns Psychol 62:14-27
Holkova, Beata; Kmieciak, Maciej; Perkins, E Brent et al. (2014) Phase I trial of bortezomib (PS-341; NSC 681239) and ""nonhybrid"" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res 20:5652-62
Lo, D J; Farris, A B; Song, M et al. (2013) Inhibition of ?v?6 promotes acute renal allograft rejection in nonhuman primates. Am J Transplant 13:3085-93
Jones, Robert; Vuky, Jacqueline; Elliott, Tony et al. (2013) Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer. Invest New Drugs 31:1001-7
Al Hawaj, M A; Martin, E J; Venitz, J et al. (2013) Monitoring rFVIII prophylaxis dosing using global haemostasis assays. Haemophilia 19:409-14
Noureddin, Mazen; Yates, Katherine P; Vaughn, Ivana A et al. (2013) Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology 58:1644-54
Lo, D J; Anderson, D J; Weaver, T A et al. (2013) Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion. Am J Transplant 13:320-8

Showing the most recent 10 out of 367 publications